TREO Foundation reveals 2023 ASMBS Research Grants
The TREO Foundation, formerly the American Society for Metabolic and Bariatric Surgery (ASMBS) Foundation, has awarded two research...
top of page
Browse by category
Search
CPAP reduces risk of dying from cardiovascular disease for patients with obstructive sleep apnoea
People suffering with obstructive sleep apnoea (OSA) can reduce their risk of dying from cardiovascular disease if they use a continuous...
AGA supports reintroduction of bipartisan Treat and Reduce Obesity Act
The American Gastroenterological Association (AGA) has announced support for the reintroduced Treat and Reduce Obesity Act (TROA), which...
Benefits of Tele-CBT for post-bariatric surgery patients
Telephone cognitive behavioural therapy (Tele-CBT) intervention is helpful in reducing symptoms of depression, anxiety, binge eating and...
Increased cardiovascular risks for people with obstructive sleep apnoea
Researchers have found that people with have an increased cardiovascular risk due to reduced blood oxygen levels, largely explained by...
Obesogens generate misinformation and drive obesity
Boston University School of Medicine researchers have proposed that obesogens - certain chemical compounds that are hypothesized to...
Individualised obesity therapy - tailoring interventions to a person's phenotypes
Phenotype-tailored lifestyle interventions may result in significant weight loss according to the results from a pilot study of 165...
EMA reviewing data after reports of suicidal thoughts and thoughts of self-harm after taking GLP-1a
The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) is reviewing data on the risk of suicidal...
Low adherence and increased cost in first year of taking GLP-1a drugs for weight loss
An analysis of real-world integrated pharmacy and medical claims data by leading pharmacy benefit manager Prime Therapeutics and Magellan...
NICE needs more evidence before recommending tirzepatide for T2DM treatment
The UK’s National Institute for Health and Care Excellence (NICE) has not recommended tirzepatide (Mounjaro, developed by Eli Lilly) in...
Browse by tag
bottom of page